The Federal Agency for Disruptive Innovation - SPRIND GmbH ("SPRIND") - aims to create new disruptive innovations from Germany. That means products, services and systems that make all our lives noticeably and sustainably better. To achieve this, SPRIND brings together new thinkers from science and business, people with outstanding ideas, special expertise, and passion. Hence, SPRIND provides an entrepreneurial environment that turns ideas into reality. The objective of BiconY Therapeutics GmbH, a SPRIND subsidiary, is the development of a bispecific antibody combination for the treatment of solid tumours. The combination consists of proprietary, bispecific CD3 anti-bodies (bsAbCD3) and bispecific CD28 co-stimulators (BiCos), which, when used together, significantly improve the specificity, sustainability, and efficiency of a T cell recruitment and thus the immune response against tumour cells. The aim of the research and development activities is to provide proof of concept for the effect of bispecific antibody therapy in the form of two phase I/IIa clinical trials. For the conduct of the planned phase I/IIa clinical trials, comprehensive central laboratory services are required for the collection logistics, processing, analysis, management, distribution and long-term storage of the biological specimens obtained from the trial participants. This includes in particular the analysis of cytokines in serum and the isolation of peripheral blood mononuclear cells (PBMC). Therefore, BiconY is looking for a service provider to act as central laboratory for these clinical trials. Please refer to the tender documents for further details.
Deadline
Die Frist für den Eingang der Angebote war 2026-11-04.
Die Ausschreibung wurde veröffentlicht am 2026-10-03.
Auftragsbekanntmachung (2026-10-03) Objekt Umfang der Beschaffung
Titel: Central Laboratory Services for Clinical Trial
Referenznummer: BiconY 02/2026
Kurze Beschreibung:
The Federal Agency for Disruptive Innovation - SPRIND GmbH ("SPRIND") - aims to create new disruptive innovations from Germany. That means products, services and systems that make all our lives noticeably and sustainably better. To achieve this, SPRIND brings together new thinkers from science and business, people with outstanding ideas, special expertise, and passion. Hence, SPRIND provides an entrepreneurial environment that turns ideas into reality. The objective of BiconY Therapeutics GmbH, a SPRIND subsidiary, is the development of a bispecific antibody combination for the treatment of solid tumours. The combination consists of proprietary, bispecific CD3 anti-bodies (bsAbCD3) and bispecific CD28 co-stimulators (BiCos), which, when used together, significantly improve the specificity, sustainability, and efficiency of a T cell recruitment and thus the immune response against tumour cells. The aim of the research and development activities is to provide proof of concept for the effect of bispecific antibody therapy in the form of two phase I/IIa clinical trials. For the conduct of the planned phase I/IIa clinical trials, comprehensive central laboratory services are required for the collection logistics, processing, analysis, management, distribution and long-term storage of the biological specimens obtained from the trial participants. This includes in particular the analysis of cytokines in serum and the isolation of peripheral blood mononuclear cells (PBMC). Therefore, BiconY is looking for a service provider to act as central laboratory for these clinical trials. Please refer to the tender documents for further details.
The Federal Agency for Disruptive Innovation - SPRIND GmbH ("SPRIND") - aims to create new disruptive innovations from Germany. That means products, services and systems that make all our lives noticeably and sustainably better. To achieve this, SPRIND brings together new thinkers from science and business, people with outstanding ideas, special expertise, and passion. Hence, SPRIND provides an entrepreneurial environment that turns ideas into reality. The objective of BiconY Therapeutics GmbH, a SPRIND subsidiary, is the development of a bispecific antibody combination for the treatment of solid tumours. The combination consists of proprietary, bispecific CD3 anti-bodies (bsAbCD3) and bispecific CD28 co-stimulators (BiCos), which, when used together, significantly improve the specificity, sustainability, and efficiency of a T cell recruitment and thus the immune response against tumour cells. The aim of the research and development activities is to provide proof of concept for the effect of bispecific antibody therapy in the form of two phase I/IIa clinical trials. For the conduct of the planned phase I/IIa clinical trials, comprehensive central laboratory services are required for the collection logistics, processing, analysis, management, distribution and long-term storage of the biological specimens obtained from the trial participants. This includes in particular the analysis of cytokines in serum and the isolation of peripheral blood mononuclear cells (PBMC). Therefore, BiconY is looking for a service provider to act as central laboratory for these clinical trials. Please refer to the tender documents for further details.
Art des Vertrags: Dienstleistungen
Produkte/Dienstleistungen: Dienstleistungen des Gesundheitswesens📦
Sonstige Beschränkungen am Erfüllungsort: Ort im Europäischen Wirtschaftsraum
Beschreibung
Interne Kennung: BiconY 02/2026
Beschreibung der Beschaffung:
The Federal Agency for Disruptive Innovation - SPRIND GmbH ("SPRIND") - aims to create new disruptive innovations from Germany. That means products, services and systems that make all our lives noticeably and sustainably better. To achieve this, SPRIND brings together new thinkers from science and business, people with outstanding ideas, special expertise, and passion. Hence, SPRIND provides an entrepreneurial environment that turns ideas into reality. The objective of BiconY Therapeutics GmbH, a SPRIND subsidiary, is the development of a bispecific antibody combination for the treatment of solid tumours. The combination con-sists of proprietary, bispecific CD3 anti-bodies (bsAbCD3) and bispecific CD28 co-stimulators (BiCos), which, when used together, significantly im-prove the specificity, sus-tainability, and efficiency of a T cell recruitment and thus the immune response against tumour cells. The aim of the research and development activities is to provide proof of con-cept for the effect of bispecific antibody therapy in the form of two phase I/IIa clinical trials. For the conduct of the planned phase I/IIa clinical trials, comprehensive central laboratory services are required for the collection logistics, processing, analysis, management, distri-bution and long-term storage of the biological specimens obtained from the trial participants. This includes in particular the analysis of cytokines in serum and the isolation of peripheral blood mononuclear cells (PBMC). Therefore, BiconY is looking for a service provider to act as central laboratory for these clinical trials. Please refer to the tender documents for further details.
The Federal Agency for Disruptive Innovation - SPRIND GmbH ("SPRIND") - aims to create new disruptive innovations from Germany. That means products, services and systems that make all our lives noticeably and sustainably better. To achieve this, SPRIND brings together new thinkers from science and business, people with outstanding ideas, special expertise, and passion. Hence, SPRIND provides an entrepreneurial environment that turns ideas into reality. The objective of BiconY Therapeutics GmbH, a SPRIND subsidiary, is the development of a bispecific antibody combination for the treatment of solid tumours. The combination con-sists of proprietary, bispecific CD3 anti-bodies (bsAbCD3) and bispecific CD28 co-stimulators (BiCos), which, when used together, significantly im-prove the specificity, sus-tainability, and efficiency of a T cell recruitment and thus the immune response against tumour cells. The aim of the research and development activities is to provide proof of con-cept for the effect of bispecific antibody therapy in the form of two phase I/IIa clinical trials. For the conduct of the planned phase I/IIa clinical trials, comprehensive central laboratory services are required for the collection logistics, processing, analysis, management, distri-bution and long-term storage of the biological specimens obtained from the trial participants. This includes in particular the analysis of cytokines in serum and the isolation of peripheral blood mononuclear cells (PBMC). Therefore, BiconY is looking for a service provider to act as central laboratory for these clinical trials. Please refer to the tender documents for further details.
Dauer: 18 Monate
Maximale Verlängerungen: 2
Weitere Informationen zur Verlängerung: There is the option to extend the contract.
Titel
Los-Identifikationsnummer: LOT-0001
Verfahren Art des Verfahrens
Offenes Verfahren ✅
Rechtsgrundlage: Richtlinie 2014/24/EU
Zentrale Elemente des Verfahrens: This is an e open procedure. No negoatiations will take place.
Beschleunigtes Verfahren:
The current service provider has informed the Client (contracting entity, BiconY Therapeu-tics GmbH, hereinafter also called "BiconY") recently in March 2026 that he will be discontinuing his business operations, with operational activities expected to wind down by end of June. The Client will receive batch releases by end of April from their Contract Manufac-turing Organization (CMO) and must ship it to the new, long term service provider. For this reason, there is a case of urgency that could not have been foreseen by the Client.
The current service provider has informed the Client (contracting entity, BiconY Therapeu-tics GmbH, hereinafter also called "BiconY") recently in March 2026 that he will be discontinuing his business operations, with operational activities expected to wind down by end of June. The Client will receive batch releases by end of April from their Contract Manufac-turing Organization (CMO) and must ship it to the new, long term service provider. For this reason, there is a case of urgency that could not have been foreseen by the Client.
Administrative Informationen
Frist für den Eingang von Angeboten oder Teilnahmeanträgen: 2026-11-04 11:00:00 📅
Bedingungen für die Öffnung der Angebote: 2026-11-04 11:01:00 📅
Sprachen, in denen Angebote oder Teilnahmeanträge eingereicht werden können: Englisch 🗣️
Mindestzeitraum, in dem der Bieter das Angebot aufrechterhalten muss: 8 Wochen Bedingungen für die Einreichung eines Angebots
Die Bieter können mehrere Angebote einreichen
Eine Sicherheitsleistung ist erforderlich ✅
Die Namen und beruflichen Qualifikationen des zur Auftragsausführung eingesetzten Personals sind anzugeben
Eröffnungstermin: 2026-11-04 11:01:00 📅
Elektronische Rechnungsstellung: Erforderlich
Die elektronische Bestellung wird verwendet ✅
Elektronische Zahlung wird verwendet ✅
Frist für die Anforderung zusätzlicher Informationen: 2026-10-26 23:59:59 📅
Zusätzliche Informationen:
Bicony asks - within its discretion - the bidder to submit, complete or correct documents, within the framework laid down by law.
Der Vertrag enthält Bedingungen zur Vertragsausführung ✅
Rechtliche, wirtschaftliche, finanzielle und technische Informationen Bedingungen für die Teilnahme
Eignungskriterium: Referenzen zu bestimmten Dienstleistungen
Liste und kurze Beschreibung der Regeln und Kriterien:
Please provide the following references. Please use the form provided for this purpose (03_Self-declaration for the eligibility of tenderers) At least five references as central laboratory in clinical studies with cytokine multiplex analysis and/or specimen management since October 1, 2022, (it is sufficient that the studies were provided in the reference period in the specified reference project, e.g., a reference that began on January 1, 2022, and ended on February 1, 2023, would be sufficient). Each reference must be either completed or ongoing. In the case of an ongoing reference, specifications of the planned/contractual project duration and information on the current status must be included. It is irrelevant whether the reference provider is a public or private company. BiconY reserves the right to verify the listed studies with the sponsors. Minimum requirements for each of the five references: 1. Since October 1, 2022 2. Completed and ongoing reference; if ongoing, specifications of the planned/contractual project duration and information on the current status of the reference project must be included 3. The respective reference must be as central laboratory in clinical studies with cytokine multiplex analysis and/or specimen management.
Liste und kurze Beschreibung der Regeln und Kriterien
Please provide the following references. Please use the form provided for this purpose (03_Self-declaration for the eligibility of tenderers) At least five references as central laboratory in clinical studies with cytokine multiplex analysis and/or specimen management since October 1, 2022, (it is sufficient that the studies were provided in the reference period in the specified reference project, e.g., a reference that began on January 1, 2022, and ended on February 1, 2023, would be sufficient). Each reference must be either completed or ongoing. In the case of an ongoing reference, specifications of the planned/contractual project duration and information on the current status must be included. It is irrelevant whether the reference provider is a public or private company. BiconY reserves the right to verify the listed studies with the sponsors. Minimum requirements for each of the five references: 1. Since October 1, 2022 2. Completed and ongoing reference; if ongoing, specifications of the planned/contractual project duration and information on the current status of the reference project must be included 3. The respective reference must be as central laboratory in clinical studies with cytokine multiplex analysis and/or specimen management.
Eignungskriterium: Zertifikate von unabhängigen Stellen über Qualitätssicherungsstandards
Liste und kurze Beschreibung der Regeln und Kriterien:
Accreditation / GCLP: The central laboratory is accredited according to ISO 15189 (or equivalent, e.g. CAP/CLIA) and operates in compliance with GCP/GCLP (Good Clinical Laboratory Practice). If more than one facility is involved, a separate accreditation / certificate needs to be available for each. A copy of the relevant certificate must be attached to the tender.
Liste und kurze Beschreibung der Regeln und Kriterien
Accreditation / GCLP: The central laboratory is accredited according to ISO 15189 (or equivalent, e.g. CAP/CLIA) and operates in compliance with GCP/GCLP (Good Clinical Laboratory Practice). If more than one facility is involved, a separate accreditation / certificate needs to be available for each. A copy of the relevant certificate must be attached to the tender.
Eignungskriterium: Maßnahmen zur Sicherstellung der Qualität
Liste und kurze Beschreibung der Regeln und Kriterien:
Self-Declaration on compliance with Good Clinical Practice (ICH E6) and with applicable data-protection requirements (GDPR / Regulation (EU) 2016/679) for the handling of human biological specimens and associated data, together with the relevant imple-mented national law (or comparable rules where a provision is not applicable to the bidder/bidding consortium).
Liste und kurze Beschreibung der Regeln und Kriterien
Self-Declaration on compliance with Good Clinical Practice (ICH E6) and with applicable data-protection requirements (GDPR / Regulation (EU) 2016/679) for the handling of human biological specimens and associated data, together with the relevant imple-mented national law (or comparable rules where a provision is not applicable to the bidder/bidding consortium).
Bedingungen für den Vertrag
Bedingungen für die Vertragserfüllung: Place of performance: Company and central labor is based in the EU.
Bedingungen für die Teilnahme
Ausschlussgrund:
Beteiligung an einer kriminellen Vereinigung
Betrug
Der Zahlungsunfähigkeit vergleichbare Lage gemäß nationaler Rechtsvorschriften
+ 19 weitere
Direkte oder indirekte Beteiligung an der Vorbereitung des Vergabeverfahrens
Einstellung der gewerblichen Tätigkeit
Geldwäsche oder Terrorismusfinanzierung
Interessenkonflikt aufgrund seiner Teilnahme an dem Vergabeverfahren
Kinderarbeit und andere Formen des Menschenhandels
Korruption
Schwerwiegendes berufliches Fehlverhalten
Terroristische Straftaten oder Straftaten im Zusammenhang mit terroristischen Aktivitäten
Täuschung, Zurückhaltung von Informationen, Unfähigkeit zur Vorlage erforderlicher Unterlagen oder Erlangung vertraulicher Informationen zu dem Verfahren
Vereinbarungen mit anderen Wirtschaftsteilnehmern zur Verzerrung des Wettbewerbs
Verstoß gegen arbeitsrechtliche Verpflichtungen
Verstoß gegen die in den rein innerstaatlichen Ausschlussgründen verankerten Verpflichtungen
Verstoß gegen die Verpflichtung zur Entrichtung von Sozialversicherungsbeiträgen
Verstoß gegen die Verpflichtung zur Entrichtung von Steuern
Verstoß gegen sozialrechtliche Verpflichtungen
Verstoß gegen umweltrechtliche Verpflichtungen
Verwaltung der Vermögenswerte durch einen Insolvenzverwalter
Vorzeitige Beendigung, Schadensersatz oder andere vergleichbare Sanktionen
Zahlungsunfähigkeit
Beschreibung der Ausschlussgründe: In accordance with §§ 123,124 GWB, § 22 LkSG
Ergänzende Informationen Zusätzliche Informationen
#Bekanntmachungs-ID: CXP4D9LM2JY#
Körper überprüfen
Name: Vergabekammer des Budnes
Nationale Registrierungsnummer: 022894990
Postanschrift: Kaiser-Friedrich-Straße 16
Postleitzahl: 53113
Postort: Bonn
Region: Bonn, Kreisfreie Stadt
🏙️
Land: Deutschland 🇩🇪
Kontaktperson: Vergabekammer des Bundes beim Bundeskartellamt
E-Mail: vk@bundeskartellamt.bund.de📧
Fax: +492289499163 📠 Verfahren zur Überprüfung
Genaue Informationen über Fristen für Überprüfungsverfahren:
According to Article 160, Section 3 of the German Act Against Restraint of Competition (GWB), application for review is not permissible insofar as 1. the applicant has identified the claimed infringement of the procurement rules before submitting the application for review and has not submitted a complaint to the contracting authority within a period of 10 calendar days; the expiry of the period pursuant to Article 134, Section 2 remains unaffected, 2. complaints of infringements of procurement rules that are evident in the tender notice are not submitted to the contracting authority at the latest by the expiry of the deadline for the application or by the deadline for the submission of bids, specified in the tender notice. 3. complaints of infringements of procurement rules that first become evident in the tender documents are not submitted to the contracting authority at the latest by the expiry of the deadline for application or by the deadline for the submission of bids, 4. more than 15 calendar days have expired since receipt of notification from the contracting authority that it is unwilling to redress the complaint, 5. there is a manifest abuse of the right to make an application or lodge a complaint in accordance with section 180(2). Sentence 1 does not apply in the case of an application to determine the invalidity of the contract in accordance with Article 135, Section 1 (2). Article 134, Section 1, Sentence 2 remains unaffected.
Genaue Informationen über Fristen für Überprüfungsverfahren
According to Article 160, Section 3 of the German Act Against Restraint of Competition (GWB), application for review is not permissible insofar as 1. the applicant has identified the claimed infringement of the procurement rules before submitting the application for review and has not submitted a complaint to the contracting authority within a period of 10 calendar days; the expiry of the period pursuant to Article 134, Section 2 remains unaffected, 2. complaints of infringements of procurement rules that are evident in the tender notice are not submitted to the contracting authority at the latest by the expiry of the deadline for the application or by the deadline for the submission of bids, specified in the tender notice. 3. complaints of infringements of procurement rules that first become evident in the tender documents are not submitted to the contracting authority at the latest by the expiry of the deadline for application or by the deadline for the submission of bids, 4. more than 15 calendar days have expired since receipt of notification from the contracting authority that it is unwilling to redress the complaint, 5. there is a manifest abuse of the right to make an application or lodge a complaint in accordance with section 180(2). Sentence 1 does not apply in the case of an application to determine the invalidity of the contract in accordance with Article 135, Section 1 (2). Article 134, Section 1, Sentence 2 remains unaffected.
Informationen über elektronische Arbeitsabläufe
Die elektronische Rechnungsstellung wird akzeptiert
Bekanntmachungsangaben
Bevorzugtes Datum der Veröffentlichung: 2026-10-03+02:00 📅
Quelle: OJS 2026/S 193-688024 (2026-10-03)